Question 1 of 48 1.0 1.0 Points
What is the mechanistic basis for the efficacy of antimetabolite anticancer
drugs?
A. The majority of tumour cells have abnormal regulation of S-
phase and cell cycle progression
B. Tumour cells overexpress P-glycoprotein, concentrating the
drug in the cell
C. Only tumour cells actively replicate DNA and RNA
D. Tumours do not develop resistance to these drugs
, Answer Key: A
Question 2 of 48 0.0 1.0 Points
Deruxtecan has the same mechanism of action as etoposide. The
mechanism of action of a Herceptin-deruxtecan conjugate involves the
following:
A. Inhibiting Her2 signaling and interfering with proper
DNA replication
B. Inhibiting Her2 signaling and interfering with mitotic
spindle formation
C. Binding to DNA, creating adducts that result in cell death
D. Binding to EGF receptors, and delivering conjugated toxins to
cancer cells
Answer Key: A
Question 3 of 48 1.0 1.0 Points
The company Downwithtumours has developed a drug called Minitro,
which targets P-glycoprotein for degradation. Patients taking Minitro would
likely not benefit additionally from therapy with the following drug:
A. Bleomycin
B. 6-MP
C. Vincristine
D. Doxorubicin
, Answer Key: B
Question 4 of 48 0.0 1.0 Points
Which of the following is NOT a mechanism involved in the elimination of
tumour cells via immunotherapy antibody approaches?
A. Interfering with the activation of lymphocytes by inhibiting
the PD-1 receptor
B. Binding of antibodies to HER2 receptors, preventing their
mitogenic signalling
C. Delivering toxins to the tumour cells in a targeted fashion
D. Binding of antibodies to the tumour cell membrane,
flagging it for phagocytosis by macrophages
Answer Key: A
Question 5 of 48 1.0 1.0 Points
Some lung tumours are treated with drugs such as erlotinib (an inhibitor of
growth factor receptors) together with paclitaxel:
A. To minimize the risk of development of drug resistance
in tumour cells
B. Erlotinib/paclitaxel combinations fit guidelines of
health insurance plans
C. To promote the emergence of drug resistance in tumour cells
D. To maximize cell kill by using two drugs with a similar
mechanism of action
What is the mechanistic basis for the efficacy of antimetabolite anticancer
drugs?
A. The majority of tumour cells have abnormal regulation of S-
phase and cell cycle progression
B. Tumour cells overexpress P-glycoprotein, concentrating the
drug in the cell
C. Only tumour cells actively replicate DNA and RNA
D. Tumours do not develop resistance to these drugs
, Answer Key: A
Question 2 of 48 0.0 1.0 Points
Deruxtecan has the same mechanism of action as etoposide. The
mechanism of action of a Herceptin-deruxtecan conjugate involves the
following:
A. Inhibiting Her2 signaling and interfering with proper
DNA replication
B. Inhibiting Her2 signaling and interfering with mitotic
spindle formation
C. Binding to DNA, creating adducts that result in cell death
D. Binding to EGF receptors, and delivering conjugated toxins to
cancer cells
Answer Key: A
Question 3 of 48 1.0 1.0 Points
The company Downwithtumours has developed a drug called Minitro,
which targets P-glycoprotein for degradation. Patients taking Minitro would
likely not benefit additionally from therapy with the following drug:
A. Bleomycin
B. 6-MP
C. Vincristine
D. Doxorubicin
, Answer Key: B
Question 4 of 48 0.0 1.0 Points
Which of the following is NOT a mechanism involved in the elimination of
tumour cells via immunotherapy antibody approaches?
A. Interfering with the activation of lymphocytes by inhibiting
the PD-1 receptor
B. Binding of antibodies to HER2 receptors, preventing their
mitogenic signalling
C. Delivering toxins to the tumour cells in a targeted fashion
D. Binding of antibodies to the tumour cell membrane,
flagging it for phagocytosis by macrophages
Answer Key: A
Question 5 of 48 1.0 1.0 Points
Some lung tumours are treated with drugs such as erlotinib (an inhibitor of
growth factor receptors) together with paclitaxel:
A. To minimize the risk of development of drug resistance
in tumour cells
B. Erlotinib/paclitaxel combinations fit guidelines of
health insurance plans
C. To promote the emergence of drug resistance in tumour cells
D. To maximize cell kill by using two drugs with a similar
mechanism of action
